Skip to main content
. Author manuscript; available in PMC: 2018 Sep 11.
Published in final edited form as: SLAS Discov. 2018 Mar 13;23(8):823–831. doi: 10.1177/2472555218763310

Figure 2.

Figure 2

Screening results. (A) Schematic of primary screening assay using MDCK cells expressing HRP-ΔF508-NBD1. Small molecules that correct the folding defect and/or stabilize ΔF508-NBD1 will increase the ΔF508-NBD1 cell surface expression as read out by the increased HRP luminescence signal. (B) Summary of primary screen showing data for all compounds, with cells expressing HRP-wild-type-NBD1 as the positive control. (C) Chemical structures of active compounds identified from the screen.